Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P24158

UPID:
PRTN3_HUMAN

ALTERNATIVE NAMES:
AGP7; C-ANCA antigen; Leukocyte proteinase 3; Neutrophil proteinase 4; P29; Wegener autoantigen

ALTERNATIVE UPACC:
P24158; P15637; P18078; Q4VB08; Q4VB09; Q6LBM7; Q6LBN2; Q9UD25; Q9UQD8

BACKGROUND:
Myeloblastin, identified by multiple aliases such as Neutrophil proteinase 4 and Wegener autoantigen, is a critical enzyme in the degradation of key structural proteins in vitro. It activates receptor F2RL1/PAR-2, contributing to vascular integrity and has a speculated role in neutrophil migration, associated with CD177.

THERAPEUTIC SIGNIFICANCE:
The exploration of Myeloblastin's functions offers a promising avenue for drug discovery. Its significant role in maintaining endothelial cell barrier function and immune cell migration presents it as an intriguing target for developing novel treatments for immune and vascular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.